| 摘要 |
The present invention relates to a method for screening an individual for the presence in his/her genome of a genetic marker that is indicative of an increased risk of deep venous thrombosis, wherein the genetic marker is haplotype 2 of the fibrinogen gamma gene (FGG-H2) as given in FIG. 5A. The genetic marker comprises a set of one, two, three or four mutations in the nucleic acid material encoding fibrinogen gamma, the mutations being selected from the group consisting of 129A/T (rs2066854), 7874G/A (rs2066861), 9615C/T (rs2066864) and 10034C/T (rs2066865). |
